Chandra Bhagat Pharma Ltd
Fundamental Score
Chandra Bhagat Pharma Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of CBPL across key market metrics for learning purposes.
Positive Indicators
4 factors identified
Excellent EPS Growth (18.03% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential and effective capital allocation over extended periods.
Strong Profit Growth Track Record (18.03% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.
Balanced Promoter Holding (72.19%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
13 factors identified
Below-Average Return on Equity (2.41%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (6.00%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation. Review business model and competitive positioning.
Margin Pressure Concerns (0.24%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges. Monitor for operational improvements.
Premium Valuation Risk (P/E: 47.10x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations. Consider entry timing carefully.
Profit Decline Concern (-33.82%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes. Monitor for recovery signs and management guidance.
Revenue Contraction (-60.64%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions and competitive positioning. Monitor recovery strategies.
Limited Growth History (-1.59% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities. Assess future growth catalysts.
Weak Interest Coverage (1.60x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability. Monitor cash flow and debt reduction plans.
Limited Institutional Interest (FII+DII: 0.61%)
Observation: Low institutional participation may affect liquidity and visibility.
Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
Very Low ROE
Observation: Poor capital utilization and shareholder returns.
Analysis: ROE below 5% suggests significant inefficiencies in capital deployment.
High P/E Ratio
Observation: Stock may be overvalued relative to earnings.
Analysis: P/E above 30 requires strong growth execution to justify current valuations.
Small Market Cap
Observation: Higher investment risk due to limited size.
Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.
Financial Statements
Comprehensive financial data for Chandra Bhagat Pharma Ltd
About CBPL
Business Overview
Chandra Bhagat Pharma Limited engages in the marketing of pharmaceutical critical care and health care products in India and internationally. It offers pharmaceutical formulations, including intravenous and intramuscular injections, tablets, and capsules in various therapeutic categories, such as anti-cancer, antibiotics, anesthesia, hormones, orthopedic, cardiac, cardiovascular, anti-fungal, antiviral, pediatrics, cardiology, nephrology, and neurology to Hospitals and Health care Centers through distribution networks and sales force under its own brand. The company also promotes and markets specialty chemicals, as well as intermediates and active pharmaceuticals ingredients. It also exports its products. The company was founded in 1944 and is headquartered in Mumbai, India.
Company Details
Key Leadership
CBPL Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Chandra Bhagat Pharma Ltd (CBPL)?
As of 30 Jan 2026, 01:40 pm IST, Chandra Bhagat Pharma Ltd (CBPL) is currently trading at ₹42.10. The stock has a market capitalization of ₹29.20 (Cr).
Is CBPL share price Overvalued or Undervalued?
CBPL is currently trading at a P/E ratio of 47.10x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Overvalued against its sector peers.
What factors affect the Chandra Bhagat Pharma Ltd share price?
Key factors influencing CBPL's price include its quarterly earnings growth (Sales Growth: -60.64%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Chandra Bhagat Pharma Ltd a good stock for long-term investment?
Chandra Bhagat Pharma Ltd shows a 5-year Profit Growth of 18.03% and an ROE of 2.41%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.69 before investing.
How does Chandra Bhagat Pharma Ltd compare with its industry peers?
Chandra Bhagat Pharma Ltd competes with major peers in the Pharmaceuticals. Investors should compare CBPL's P/E of 47.10x and ROE of 2.41% against the industry averages to determine its competitive standing.
What is the P/E ratio of CBPL and what does it mean?
CBPL has a P/E ratio of 47.10x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹47 for every ₹1 of annual earnings.
How is CBPL performing according to Bull Run's analysis?
CBPL has a Bull Run fundamental score of 26.3/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does CBPL belong to?
CBPL operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Chandra Bhagat Pharma Ltd.
What is Return on Equity (ROE) and why is it important for CBPL?
CBPL has an ROE of 2.41%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Chandra Bhagat Pharma Ltd generates profits from shareholders' equity.
How is CBPL's debt-to-equity ratio and what does it indicate?
CBPL has a debt-to-equity ratio of 0.69, which indicates moderate leverage that should be monitored. A ratio below 1.0 generally indicates conservative financing.
What is CBPL's dividend yield and is it a good dividend stock?
CBPL offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has CBPL grown over the past 5 years?
CBPL has achieved 5-year growth rates of: Sales Growth -1.59%, Profit Growth 18.03%, and EPS Growth 18.03%.
What is the promoter holding in CBPL and why does it matter?
Promoters hold 72.19% of CBPL shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is CBPL's market capitalization category?
CBPL has a market capitalization of ₹29 crores, placing it in the Small-cap category.
How volatile is CBPL stock?
CBPL has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for CBPL?
CBPL has a 52-week high of ₹N/A and low of ₹N/A.
What is CBPL's operating profit margin trend?
CBPL has a 5-year average Operating Profit Margin (OPM) of 0.24%, indicating the company's operational efficiency.
How is CBPL's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of -60.64% and YoY Profit Growth of -33.82%.
What is the institutional holding pattern in CBPL?
CBPL has FII holding of 0.61% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the stock.